Category Archives: Drug Market Info News
Mary Beth Cicero: Why I’m Walking in the Great Strides Walk for Cystic Fibrosis May 20
May is Cystic Fibrosis Awareness Month and one of the largest national fundraising events takes place this Sunday. It is the Great Strides Walk, which is taking place in over 200 cities this Saturday and Sunday, May 19-20. (Click to find out more about Great Strides, including walk locations.)
I will actually be walking twice! Last year when Drug Market Info was looking for CF patients to interview for our Cystic Fibrosis Market Info report, I contacted my good friend Sue (whom I hadn’t seen in years) but knew her daughter had CF. We ended up interviewing her and a number of her friends from western Massachusetts and were completely touched by their stories.
Our interviews with these patients and caregivers took place last November and they mentioned the Great Strides Walk to me. I promised them that I would be there and so here it is May and I am on my way to both Northampton and Shelburne Falls Mass. I will be supporting Team Paige and Audrey’s Angels.
I am so excited because I will be meeting some of the patients and mothers we interviewed that contributed so many insights to our Cystic Fibrosis Market Info report. I truly hope that the patients’ perspectives they shared will influence companies to either undertake further drug development on Cystic Fibrosis or take their needs into account. (You can get the facts on Cystic Fibrosis here.)
I am particularly excited to meet in person one of the patients we talked with that has had 2 lung transplants—she touched my heart and I can’t wait to meet her! When I asked her about her goals in life she said she didn’t have any. Her mother interjected that she doesn’t know how long she will live and doesn’t like to think about the future. Of course, I jumped in and said, “Why don’t you want to be the first person to have 3 lung transplants!” I am hoping that won’t have to happen and that she will thrive and be happy.
She did mention that she always wanted to go skydiving. Even though I want to make her happy… I am drawing the line at skydiving! However, I am going to take her zip lining and I am happy to report that Bob Coughlin (President of Mass BIO, read our Notes & Notable interview with Bob Coughlin) who has a son with CF is not as “chicken” as me and has graciously agreed to take her sky diving.
To all of you out there with CF and to those who love you, as well as all of the drug researchers trying to cure this disease—I salute you and will be proudly walking alongside of you on Sunday.
Share this:
Drug Market Info Launches New Prostate Cancer Market Info™
DRUG MARKET INFO LAUNCHES NEW PROSTATE CANCER MARKET INFO™
Comprehensive Presentation-ready Report on Prostate Cancer Covers All Treatment Options and Up-to-date Market Information with Patients’ Perspectives
NORWELL, MA– March 27, 2012- Drug Market Info®, the only source for presentation-ready market reports with the Patient’s Perspective, announced today the launch of its newest research report – Prostate Cancer Market Info™. Prostate cancer is a common cancer found in men, and has the second leading cancer-related mortality rate behind lung cancer. Prostate Cancer Market Info™ is a comprehensive look at the market, including current market data, diagnosis statistics, and treatment options, as well as patient estimates by disease stage.
Prostate Cancer is a malignant adenocarcinoma that grows as small tumors in different locations throughout a man’s prostate gland. Some tumors are indolent and require no treatment, but others are aggressive and life-threatening. Currently, there is no way to tell tumor aggressiveness and no clear guidelines about how to manage the disease, or which treatment option works best. Recently, several new products for the later stages of Prostate Cancer have been launched and according to a recent Barron’s report, the metastatic prostate-cancer market could grow from approximately $1 billion to $8 billion by the end of the decade.
Prostate Cancer Market Info™ provides a comprehensive look at the market, covering epidemiology, patient estimates by disease stage, as well as unit and sales data trended for five years. As a presentation-ready report, Prostate Cancer Market Info™ is the only market analysis that contains over 100 customizable slides, 28 graphs and charts, with patient insights and perspectives woven throughout. As with all Drug Market Info reports, Prostate Cancer Market Info™ was reviewed by a leading clinician in the field to validate disease dynamics and therapeutic approaches.
“Prostate Cancer is a disease that significantly impacts men and their families with one out of every six developing the disease and over two million men in the U.S. currently living with it,” said Mary Beth Cicero, Principal of Drug Market Info. “This new report from Drug Market Info provides unique insights on the diagnosis and treatment of prostate cancer, especially since there are a variety of choices available to physicians and their patients. The Prostate Cancer Market Info™ report examines the current landscape of available treatments and pipeline products, but more importantly, spotlights how real patients weigh their treatment options and ultimately decide upon a regimen that works best for them.”
“We see over 1,000 newly diagnosed prostate cancer patients each year,” said Judd Moul, M.D., F.A.C.S. James H. Semans, MD, Professor of Surgery Director at Duke Cancer Institute. “Every man is different, so his cancer is different and his treatment choices will be, too. Therefore, it is important that a comprehensive array of treatments be available, as well as access to clinical trials and cutting-edge therapies. Drug Market Info’s comprehensive Prostate Cancer Market Info™ thoroughly covers the patients, treatments and what is in the pipeline, and is an important resource for companies looking to better understand this disease.”
Drug Market Info develops reports based on putting patients front and center. We are strong supporters of patient advocacy and our business model is built around donating a portion of our proceeds to the leading patient advocacy group in each therapeutic area we cover. Drug Market Info is extremely proud and privileged to be associated with ZERO — The Project to End Prostate Cancer. The organization is committed to creating Generation Zero: the first generation of men free from prostate cancer. Zero prostate cancer deaths. Zero prostate cancer cases. Zero tolerance for prostate cancer. To accomplish their goal, ZERO provides comprehensive treatment information to patients, education to those at risk and conducts free prostate cancer screening throughout the country. To learn more about ZERO, visit http://zerocancer.org.
“This year alone, more than 241,000 men will be diagnosed with prostate cancer and more than 28,000 will die from the disease,” said Skip Lockwood, Chief Executive Officer of ZERO. “We are seeing the death rate decrease, but we must remain vigilant in the fight against this disease by increasing research funding, raising awareness and education, and testing men with risk factors. We are pleased to be associated with Drug Market Info for making available important data on the prostate cancer market, and for showing how the disease and treatment dramatically affects the lives of men.”
About Drug Market Info (http://www.drugmarketinfo.com/)
Have you ever just wanted to understand a disease – what it looks like, who gets it, what are the treatments, which products are used and how the market is valued? Drug Market Info was founded by experienced pharmaceutical professionals who recognized the need for current, ready-to-use market information that gets to the real core of understanding a therapeutic market. Drug Market Info reports are centered around the concept of the three P’s – Patients, Perspectives and Potential with a strong focus on patient and physician insights. Our reports provide clinically accurate, up-to-date information on treating diseases such as Psoriasis, Psoriatic Arthritis, Cystic Fibrosis and Prostate Cancer, as well as how these markets are defined, sized and valued. Unique from other industry reports on the market, Drug Market Info delivers information in a presentation-ready PowerPoint format at a reasonable price. In just minutes, you can download a customizable deck of slides covering everything you need to know about a therapeutic market and the opportunities it represents. Most importantly, only Drug Market Info provides patients’ perspectives on the disease and their treatment experiences. The Company proudly collaborates with leading Patient Advocacy Groups so that every report purchased will benefit patients with the disease.
Drug Market Info – The Patients’ Perspectives and the Info You Want Now!
For Sales Information, please contact:
Mary Beth Cicero, Principal or Pamela Porter, Chief Business Officer
Call (855) DRUGMKT (378-4658)
Twitter: @DrugMarketInfo
For Media Inquiries, please contact:
Lisa Rivero
(855) 378-4658
Share this:
Perfect Timing: Vertex Cystic Fibrosis Drug Approved and Cystic Fibrosis Market Info Report Now Available
Our Cystic Fibrosis Market Info™ Report, Drug Market Info’s newest market research report, is perfectly timed for analysts and drug developers to assess the impact of Vertex‘s new ground-breaking therapy for Cystic Fibrosis (CF), Kalydeco. It provides explicit disease information, the current drug armamentarium for CF, the five-year trend for the CF market value, detailed pricing and pertinent data on the CF pipeline. In addition, extensive patient input (our signature “patients’ perspective“) offers a glimpse into how CF and its treatment impacts lives. All of this supports our conclusion that the FDA approval of Vertex’s Kalydeco is a major step forward in the treatment of Cystic Fibrosis (CF) because…
- It validates genetic therapy — it is the first step toward a genetic cure for a disease caused by a faulty gene
- It treats the causes, not just the symptoms of the disease: First time ever for a CF therapy
- It could lower the high treatment burden of CF: Potentially decreases the medication load versus adding more to the pile
- It underscores the importance of collaborative agreements with the Cystic Fibrosis Foundation in this area: Kalydeco was discovered through a research collaboration with Vertex and the Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT)
Maybe most importantly, this paves the way for a new research and drug development approach for any genetic disorder. Kudos to Vertex!
Sue Casarona,
Vice President,
Drug Market Info
Share this:
Top Three Trends in Pharma Marketing for 2012
As part of PharmaVOICE Magazine’s year-end issue, they asked a selection of industry experts to provide their predictions of the Top Three Trends in Pharma Marketing for 2012. We are pleased to report that Drug Market Info principal Mary Beth Cicero was one of the experts they quoted in their “Year in Preview”.
It shouldn’t come as a surprise that the trends Mary Beth sees as being important for 2012 include a healthy dose of patients’ perspectives, since as a company Drug Market Info believes that listening to patients is critically important to the development and marketing of successful drugs and therapy regimens.
What were Mary Beth’s predictions?
- Getting new patients will become harder with many therapies and therefore keeping patients on treatment will be more important than ever. Adherence to therapy will be the key to growing prescriptions over time. Learning more about why patients don’t stay on therapy and why they don’t adhere to drug regimens should be a part of every marketing strategy.
- More doctors are not seeing sales representatives and this is primarily where physicians get information on new products/therapies. How to inform doctors about new products will become increasingly important as sales forces are cut.
- Patients will have access to the same information as doctors and are becoming more knowledgeable and educated about therapies than ever before. Companies will need to better understand how patients are responding – or not – to treatments and realize that therapies cannot be marketed as one-size-fits-all anymore.
You can read all the PharmaVOICE Magazine trends by clicking on the image below:
Share this:
Drug Market Info Launches Presentation-Ready Report on Cystic Fibrosis Market
Unique Cystic Fibrosis Market Info™ Report Focuses on Treatment of Orphan Disease from the Patients’ and Caregiver’s Perspective
NORWELL, Mass.–(BUSINESS WIRE)–Drug Market Info, a new Internet source for presentation-ready market reports with the Patients’ Perspective, announced today the launch of its newest research report — Cystic Fibrosis Market Info™. Cystic Fibrosis (CF) is an orphan indication that is a chronic, progressive, life-limiting autosomal recessive genetic disease that affects the lungs, digestive and reproductive systems.
“Cystic Fibrosis is a devastating disease that has, until recently, been predominantly a pediatric disease affecting tens of thousands of patients. Treatments are time consuming and costly, and the burden weighs heavily on both patients and caregivers”
There are about 30,000 patients, living with CF in the U.S., and while new treatments have added years to life expectancies, Cystic Fibrosis comes with a high treatment burden, which includes numerous and time-consuming daily medications and activities. To better understand the treatment of cystic fibrosis, as well as the market, pipeline and implications for future growth, Drug Market Info has launched a unique patient-focused report, “Cystic Fibrosis Market Info™.” This presentation-ready report is a comprehensive look at the CF market, including prescription data trended for five years. Cystic Fibrosis Market Info™ contains 90 customizable slides, 28 graphs and charts, photographs of patients and caregivers, with their insights and perspectives woven throughout. Drug Market Info’s CF report is the only market research report available today to provide patient/care-giver perspectives that highlight the struggles that are an unfortunate necessity of these daily, time-consuming treatment regimens. As with all Drug Market Info reports, Cystic Fibrosis Market Info™ was reviewed by a leading clinician in the field to provide the most current perspective on treatment and future trends.
“Cystic Fibrosis is a devastating disease that has, until recently, been predominantly a pediatric disease affecting tens of thousands of patients. Treatments are time consuming and costly, and the burden weighs heavily on both patients and caregivers,” said Mary Beth Cicero, Principal of Drug Market Info. “Drug Market Info is pleased to offer this report on a fascinating market that is not well-profiled and often overlooked from a drug development perspective. We hope that marketers will read and assimilate the perspectives shared by patients and caregivers that provide insights on treatment and what is needed.”
“While technically a rare disease, cystic fibrosis is one of the most widespread life-shortening genetic diseases in the Western World affecting 1 out of 3,700 US births or roughly 1,000 births per year,” said Brian O’Sullivan, MD, a pediatric pulmonologist and Director at the Cystic Fibrosis Center at UMass Memorial Medical Center in Worcester, MA. “More therapies are needed and it is important for those developing novel therapeutics to understand all aspects of this disease including what is now available, what is in the pipeline, and to keep in mind the patient experience and treatment burden.”
In addition to having current treatment and market information, Drug Market Info develops reports based on putting patients and caregiver’s front and center. “We are strong supporters of patient advocacy and our business model is built around donating a portion of our proceeds to the leading patient advocacy group in each therapeutic area we cover,” stated Mary Beth Cicero. Drug Market Info is extremely proud and privileged to be associated with the Boomer Esiason Foundation, and will be providing a donation for each report purchased to help CF patients. The Boomer Esiason Foundation is a dynamic partnership of leaders in the medical and business communities joining with a committed core of volunteers to heighten awareness, education and the quality of life for those affected by cystic fibrosis, while providing financial support to research aimed at finding a cure. To find out more information about this organization, please visit http://www.esiason.org.
“Every day researchers around the world are coming one step closer to finding a cure for cystic fibrosis. In the meantime, the CF drug pipeline ensures therapies are moving from the laboratory to the marketplace. Information on the CF market that highlights the opportunities and focuses on patients is needed to help this effort,” stated David Rimington, President of the Boomer Esiason Foundation. “We support the efforts of Drug Market Info for making this vital information available. We also applaud their efforts to support cystic fibrosis patients.”
Drug Market Info was founded by experienced pharmaceutical professionals who recognized the need for current, crisp, ready-to-use market information. Drug Market Info’s reports are unique in that they are organized in “presentation-ready PowerPoint format,” and centered around the concept of the three P’s – Patients, Perspectives and Potential with a strong focus on patient and physician perspectives.
About Drug Market Info
Have you ever just wanted to understand a disease – what it looks like, who gets it, what are the treatments, which products are used and why? Drug Market Info provides clinically accurate, up-to-date information on treating diseases such as Psoriasis, Psoriatic Arthritis, Cystic Fibrosis, Prostate Cancer and Parkinson’s disease, as well as how these markets are defined, sized and valued. Our market info reports deliver current, reliable information in a presentation-ready PowerPoint format at a reasonable price. In just minutes, you can download a customizable deck of slides covering everything you need to know about a disease, along with current treatment approaches and up-to-date U.S. market data trended for 5 years. Most importantly, only Drug Market Info provides patients’ insights on the disease and their treatment experiences. The Company proudly collaborates with leading patient advocacy groups so that every report purchased benefits patients with the disease.
Drug Market Info – The Patients’ Perspectives and the Info You Want Now!
Contacts
Drug Market Info
For Sales Information, please contact:
Mary Beth Cicero, Principal or Pamela Porter, Chief Business Officer
(855) DRUGMKT (378-4658)
sales@drugmarketinfo.com
Twitter: @DrugMarketInfo
or
For Media Inquiries, please contact:
Lisa Rivero, 855-378-4658
Lisa@drugmarketinfo.com
Share this:
Drug Market Info featured in “Tomorrow’s Technologies Today”
The University of Manitoba’s Technology Transfer Office is at the cutting edge, so we’re very proud to have made it into the “News, People, Places” section of their Tomorrow’s Technologies Today newsletter for September, 2011.
The write-up features a picture and quote from Mary Beth Cicero stressing how important we feel it is that to truly evaluate the markets we cover, like Psoriasis, Psoriatic Arthritis, and Cystic Fibrosis (soon to be released), it is important to understand patients and their views of disease and therapies.
Drug Market Info, providers of market reports for Psoriasis, Psoriatic Arthritis, Cystic Fibrosis and more, is featured in the September, 2011 issue of Tomorrow's Technology Today.
You can read the whole issue here.
Share this:
MarketSense and Drug Market Info to run Hot Topic workshop at LES 2011 in San Diego
Getting from Marketing to M&A (The “New” Licensing) – Data Will Prevail!
Do you want to know the secret to M&A success? Then you won’t want to miss the Hot Topic Workshop being moderated by Mary Beth Cicero, president of MarketSense, LTD and the Principal of Drug Market Info, at the LES 2011 Annual Meeting in San Diego, CA on October 18th. The workshop also features:
- Sue Casarona, Vice President of Drug Market Info
- Margaret Nelson, Manager, EvaluatePharma USA, Inc.
- David Yeary, Director, Merrill Datasite
Not only is the workshop a great place to pick up some secrets you can use to succeed, but the annual meeting of the Licensing Executives Society is a perfect time to meet with Drug Market Info. Find out about our current research reports, Psoriasis Market Info™ and Psoriatic Arthritis Market Info™ as well as our soon-to-be-released Cystic Fibrosis Market Info™.
Here are the workshop details — See you in San Diego!
WORKSHOP SESSION 4
TUESDAY, OCTOBER 18
3:45 p.m. – 5:00 p.m.
4-A: Getting from Marketing to M&A (The “New” Licensing) – Data Will Prevail!
In biotech and pharma, the successful launches of today were built on deals struck several years ago. Now with the stock market in turmoil and biotech companies trading at year-to-date lows, no one knows how upstream deal making will be affected. We do know that companies have gotten more sophisticated in evaluating healthcare products and technologies, valuing the opportunities, and structuring due diligence. To be successful with M&A — facts and data will prevail. This workshop will cover in an interactive and hands-on manner the three data tools that are necessary for the M&A process. Specifically, Market Data — the Market information and market research data that are key elements for creating the buzz around your product and valuing the opportunity. Deal Data — Deal Databases have gotten more robust and now cover extensive information fine-tuned at every level. Comparables are readily available for most deals. Data Rooms — The days of on-site due diligence and reviewing paper documents is gone and virtual data rooms have become a necessity. Learn the ins and outs of Data Rooms to position your asset in the best light and monitor the activity of partners reviewing your opportunity.
The DrugMarketInfo.com Blog 